Bisphosphonate drug holidays-when, why and for how long?

Climacteric

Volumn 18, Issue , 2015, Pages 32-38

  Anagnostis, P ^a   Stevenson, J C ^b  

^a Division of Endocrinology   (Greece)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alendronate; Atypical Fractures; Bisphosphonates; Drug Holiday; Risedronate; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE DENSITY; BONE TURNOVER; CHEMICAL STRUCTURE; FEMUR FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; OSTEOCLAST; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SPINE FRACTURE; BONE NECROSIS; CHEMICALLY INDUCED; DOSE RESPONSE; FEMALE; FRACTURES, BONE; JAW DISEASE; KIDNEY DISEASE; MALE; MIDDLE AGED; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; JAW DISEASES; KIDNEY DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; OSTEOPOROSIS; RISK FACTORS;

EID: 84948582201     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2015.1099092     Document Type: Article

References (44)

1. Watts NB, Bilezikian JP, Camacho PM., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 2010; 16 (Suppl 3): 1-37
2. Khosla S, Bilezikian JP, Dempster DW., et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012; 97: 2272-82
3. Jansen JP, Bergman GJ, Huels J, Olson M. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum 2011; 40: 275-84
4. Chen L, Wang G, Zheng F, Zhao H, Li H. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. Osteoporos Int 2015; 26: 2355-63
5. Kanis JA, Adams J, Borgström F., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008; 42: 4-15
6. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010; 95: 1174-81
7. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-59
8. Miller PD, Bolognese MA, Lewiecki EM., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43: 222-9
9. Greenspan SL, Emkey RD, Bone HG., et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 875-83
10. Khan AA, Morrison A, Hanley DA, et al.; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30: 3-23
11. Khan AA, Sándor GK, Dore E, et al.; Canadian Association of Oral and Maxillofacial Surgeons. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35: 1391-7
12. Goss AN. Bisphosphonate-associated osteonecrosis of the jaws. Climacteric 2007; 10: 5-8
13. Barasch A, Cunha-Cruz J, Curro FA., et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011; 90: 439-44
14. Hoff AO, Toth BB, Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-36
15. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-58
16. Reid IR, Cornish J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 2011; 8: 90-6
17. Hikita H, Miyazawa K, Tabuchi M, Kimura M, Goto S. Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats. J Bone Miner Metab 2009; 27: 663-72
18. Shane E, Burr D, Ebeling PR., et al. Atypical subtrochanteric and diaphyseal femoral fractures: a second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29: 1-23
19. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728-37
20. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; 28: 1729-37
21. Lee S, Yin RV, Hirpara H., et al. Increased risk for atypical fractures associated with bisphosphonate use. Fam Pract 2015; 32: 276-81
22. Meier RPH, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172: 930-6
23. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med 2008; 359: 316-17
24. Goh SK, Yang KY, Koh JS., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89: 349-53
25. Rizzoli R, Akesson K, Bouxsein M., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22: 373-90
26. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-38
27. McNabb BL, Vittinghoff E, Schwartz AV., et al. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res 2013; 28: 1319-27
28. Schwartz AV, Bauer DC, Cummings SR, et al.; FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010; 25: 976-82
29. Black DM, Kelly MP, Genant HK., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. N Engl J Med 2010; 362: 1761-71
30. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long N Engl J Med 2012; 366: 2051-3
31. Black DM, Reid IR, Boonen S., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243-54
32. Black DM, Reid IR, Cauley JA., et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015; 30: 934-44
33. Watts NB, Chines A, Olszynski WP., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008; 19: 365-72
34. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 2011; 96: 3367-73
35. Frost ML, Siddique M, Blake GM., et al. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Osteoporos Int 2012; 23: 2107-16
36. Bauer DC, Schwartz A, Palermo L., et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 2014; 174: 1126-34
37. Cosman F, Cauley JA, Eastell R., et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment J Clin Endocrinol Metab 2014; 99: 4546-54
38. McNabb B, Vittinghoff E, Eastell R., et al. A model of BMD changes after alendronate discontinuation to guide post alendronate BMD monitoring. J Clin Endocrinol Metab 2014; 99: 4094-100
39. Heiss G, Wallace R, Anderson GL., et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299: 1036-45
40. Bone HG, Bolognese MA, Yuen CK., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96: 972-80
41. Fraser LA, Vogt KN, Adachi JD, Thabane L. Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag 2011; 7: 157-66
42. Compston JE, Bilezikian JP. Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res 2012; 27: 240-2
43. Diab DL, Watts NB. Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes 2013; 20: 501-9
44. Compston J, Bowring C, Cooper A., et al.; National Osteoporosis Guideline Group. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013; 75: 392-6